Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sophie Wildsmith(AstraZeneca (United Kingdom)), Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Alejandro Yovine(AstraZeneca (United Kingdom)), Jiabu Ye(AstraZeneca (Japan)), Jérôme Fayette(Université Claude Bernard Lyon 1), Jessica Whiteley(AstraZeneca (United Kingdom)), Melissa de los Reyes(AstraZeneca (Japan)), Dan P. Zandberg(University of Pittsburgh Medical Center), Nicholas Holoweckyj(AstraZeneca (Japan)), Rajiv Raja(AstraZeneca (United States)), Lisa Licitra(University of Milan), Magdalena Wrona, Katia Real(AstraZeneca (United Kingdom)), Nassim Morsli(Boehringer Ingelheim (France)), Jagdish Shetty(AstraZeneca (United States)), Jill Walker(AstraZeneca (United Kingdom)), Weimin Li(AstraZeneca (Japan)), Song Wu(AstraZeneca (Japan)), Robert I. Haddad(Georgetown University), Robert L. Ferris(University of Pittsburgh), Craig Barker(AstraZeneca (United Kingdom)), Philip He(AstraZeneca (Japan)), Lillian L. Siu(University Health Network), Qu Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ross Stewart(AstraZeneca (United Kingdom))
Cited by 30
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k